Cboe Global Markets, Inc.

Highlights CBOE as the world’s largest options exchange whose shares sold off from around 370 to 250 on competition fears despite one of its best quarters ever, with Q1 2026 net revenue up sharply, EPS beating consensus, expanded margins, and raised organic growth guidance, arguing this fear‑driven repricing creates a compelling entry in a durable market‑infrastructure franchise while flagging emerging event and prediction‑market competitors and regulatory developments as key risks.

Discusses a trim in CBOE’s modeled fair value from roughly 330 to about 320 per share as analysts balance growth optionality in retail trading and prediction markets against competitive pressure from bitcoin perpetual futures and softer volatility‑driven trading, summarizing a range of broker views that include neutral and hold ratings, reduced price targets, and concerns about long‑term terminal value and earnings momentum even as some houses still view competitive threats as manageable.

Argues that CBOE’s sharp share‑price decline driven by fears over prediction‑market competitor Polymarket has left the stock materially undervalued versus an analyst‑derived fair value estimate around 330, noting that consensus price targets, modestly revised growth and margin assumptions, and updated discount‑rate and future P/E inputs still point to upside, while recent Street research is characterized as a mix of optimism and caution around volumes, volatility, and new product launches.

Frames CBOE’s recent 14% one‑month pullback against strong year‑to‑date and 1‑year total returns, presenting a valuation model that pegs fair value near 330 and suggests the shares are roughly 8.9% undervalued based on long‑term earnings projections, margin assumptions, and a target P/E path, while highlighting broad growth across derivatives, data services, and global spot markets along with the caveat that valuation multiples could compress if market sentiment weakens.

Profiles CBOE as a top‑rated “quality compounder” with 5‑star overall scores, high health and performance grades, and a low risk reading, emphasizing exceptional free cash flow, options‑segment operating margins above 70%, strong 52‑week outperformance versus the S&P 500, and a surging technical trend that together support a strong‑buy entry signal, while arguing that investors misprice the stock by viewing it purely as a fear trade rather than recognizing structural revenue shifts from zero‑days‑to‑expiration SPX options and growing data streams.